General
Preferred name
KETOPROFEN
Synonyms
DEXKETOPROFEN ()
RP-19583 ()
KETOPROFEN SODIUM ()
KETOPROFEN LYSINE ()
Ketozip 200 XL ()
Actron ketoprofen ()
Ketonal ()
Aneol ()
Jomethid XL ()
Powergel ()
R.P. 19583 ()
Ketorin ()
R.P. 19,583 ()
Fenoket 200 ()
Oruvail IM ()
Ketovail ()
Oruvail 150 ()
Hydratropic acid, m-benzoyl- ()
Ketocid 200 ()
Nexcede ()
Orudis Kt ()
Oruvail 200 ()
Orudis 100 ()
Larafen CR ()
Tiloket CR ()
Valket 200 Retard ()
19583RP ()
Alrheumat ()
Sector ()
Oruvail 100 ()
Larafen ()
Orudis ()
Actron ()
Capisten ()
NSC-758144 ()
(rs)-ketoprofen ()
Ketotard 200 XL ()
Iso-k ()
RU-4733 ()
IDEA-033 ()
Tiloket ()
Oruvail ()
Axorid ()
Sodium ketoprofen ()
Diractin ()
Ketoprofen lysine salt ()
Artrosilene ()
Ketoprofen l-lysinate ()
(±)-Ketoprofen-d3 ()
P&D ID
PD001443
CAS
22071-15-4
154907-35-4
57495-14-4
159490-55-8
Tags
drug candidate
natural product
drug
available
Approved by
FDA
First approval
1986
Drug Status
investigational
approved
vet_approved
Drug indication
Migraine
Osteoarthritis
Musculoskeletal pain
Pain
Anti-Inflammatory
Max Phase
Phase 2
Phase 4
Phase 1
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
TOXICITY LD50=62.4 mg/kg (rat, oral). ;

Symptoms of overdose include drowsiness, vomiting and abdominal pain.

;

Side effects are usually mild and mainly involved the GI tract. Most common adverse GI effect is dyspepsia (11% of patients). May cause nausea, diarrhea, abdominal pain, constipation and flatulence in greater than 3% of patients.

HALF-LIFE Conventional capsules: 1.1-4 hours;

Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)

DESCRIPTION The approved drug ketoprofen is a mixture of two stereoisomers; an (R)-enantiomer (see PubChem CID 180540), and an (S)-enantiomer (see PubChem CID 667550), with only the (S)-enantiomer possessing biological activity. The structure shown here does not specify stereochemistry and represents the mixture of isomers. (GtoPdb)
DESCRIPTION COX-1 selective non-steroidal anti-inflammatory (NSAID) drug (LOPAC library)
Cell lines
0
Organisms
1
Compound Sets
31
Cayman Chemical Bioactives
10006661
28148
ChEMBL Approved Drugs
CHEMBL571
ChEMBL Drugs
CHEMBL571
CHEMBL341922
CHEMBL4650345
Concise Guide to Pharmacology 2017/18
4795
Concise Guide to Pharmacology 2019/20
4795
Concise Guide to Pharmacology 2021/22
4795
Concise Guide to Pharmacology 2023/24
4795
DrugBank
DB01009
DrugBank Approved Drugs
DB01009
DrugCentral
1528
DrugCentral Approved Drugs
1528
DrugMAP
DMRKXPT
DrugMAP Approved Drugs
DMRKXPT
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101790
Guide to Pharmacology
4795
Ki Database
Ketoprofen
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL571
Mcule NIBR MoA Box Subset
MCULE-9740144074
MedChem Express Bioactive Compound Library
HY-B0227
NCATS Inxight Approved Drugs
90Y4QC304K
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Ketoprofen(Actron)
TargetMol Bioactive Compound Library
T0839
The Spectrum Collection
External IDs
73
Properties
(calculated by RDKit )
Molecular Weight
254.09
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
2
cLogP
3.11
TPSA
54.37
Fraction CSP3
0.12
Chiral centers
1.0
Largest ring
6.0
QED
0.85
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
COX-1
Pathway
Immunology/Inflammation
Neuroscience
Target
COX-2
MRAP4
COX
Member status
virtual
MOA
Non-Steroidal Antiinflammatory Drugs
Therapeutic Class
Analgesics
Source data